Immunic(US:IMUX) Yahoo Finance·2026-01-12 09:23Core Insights - Immunic, Inc. (NASDAQ:IMUX) has experienced a significant share price increase of 24.10% over the past five days as of January 9, 2026, following a review of its 2025 performance and upcoming milestones [2] Group 1: Company Performance and Milestones - The company has completed enrollment in the Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium (IMU-838) in relapsing multiple sclerosis (RMS), with 1,121 and 1,100 patients enrolled across over 100 sites in 15 countries [3] - A synchronized top-line readout is anticipated by the end of 2026 to evaluate the therapy's potential in modifying disease progression [3] - Long-term Phase 2 EMPhASIS data confirmed durable disability protection in relapsing-remitting MS (RRMS), with over 92% of patients remaining free of 24-week confirmed disability worsening after up to 5.5 years [4] Group 2: Clinical Trial Results - The Phase 2 CALLIPER trial in progressive MS demonstrated statistically significant reductions in 24-week confirmed disability worsening (24wCDW), indicating neuroprotective effects independent of inflammation [5] Group 3: Product Development and Financing - Management discussed IMU-856, a small molecule modulator targeting Sirtuin 6 (SIRT6), which has shown promising early clinical and preclinical signals for gastrointestinal barrier restoration and weight management [6] - The company plans to expand its oral immunology portfolio, supported by strong financing in 2025, including a $65 million public offering to advance its programs [6] Group 4: Company Focus - Immunic, Inc. is dedicated to developing selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases, including multiple sclerosis, ulcerative colitis, and Crohn's disease [7]